IBR Inc. is a premier site for bioanalytical services with 20 years history of performing studies on cytokines, chemokines and other biomarkers, drug/target binding and immunogenicity. Focussed on therapeutic antibodies, biologics, biosimilars, antibody-drug conjugates and vaccines the services cover the bioanalytical needs from pre-clinical and clinical development to manufacturing. The commitment of IBR Inc. to deliver high quality services is strengthened by setting high value on scientific discussion with the customers to provide them with studies tailored to their needs. IBR Inc. develops and validates cell-based assays with a broad variety of endpoints providing vast experience with primary cells, transformed cell lines, transfected cells, reporter-gene cell systems and 3D cell-based assays. Beside a broad variety of traditional methods a selection of most sought-after technology platforms including Alpha Technology, TRF, TR-FRET, MSD-ECL, Gyrolab, BD FACS Lyric, multiplex cytometric bead array and real time PCR are highlights of the service portfolio. In addition, IBR Inc. offers studies covering the GxP quality standards with reports that are compliant with the eCTD requirements.